Therapy News and Research

RSS

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

One of the challenges of understanding cancer is trying to determine the mechanisms that drive metastasis, or the process by which tumor cells are able to spread throughout the body.

19 Oct 2013

New prognostic tool forecasts survival of patients with advanced prostate cancer

For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.

19 Oct 2013

Valley Presbyterian Hospital doc awarded 2013 Achievement Award in Diabetic Limb Salvage

George Andros, MD, Founder and Medical Director of the Amputation Prevention Center at Valley Presbyterian Hospital, was honored with the MedStar Georgetown 2013 Distinguished Achievement Award in Diabetic Limb Salvage.

19 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

CBT more effective in reducing symptoms of health anxiety

Cognitive behavioural therapy (CBT) is substantially more effective than standard care at reducing symptoms of health anxiety in medical patients, and can be delivered by non-specialist staff with minimal training at little extra cost.

19 Oct 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

18 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

18 Oct 2013

Genalyte receives NCI grant to develop biomarker panel to profile TAA autoantibodies

Genalyte, Inc., today announced that it has received a $1 million SBIR grant from the National Cancer Institute to develop a biomarker panel to profile tumor antigen-associated autoantibodies.

18 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

$Vertebral augmentation for spinal fractures improves patient survival, reduces overall costs$

Vertebral augmentation for spinal fractures improves patient survival, reduces overall costs

A study of 69,000 Medicare patient records led by Johns Hopkins researchers shows that people with spine compression fractures who undergo operations to strengthen back bones with cement survive longer and have shorter overall hospital stays than those who stick with bed rest, pain control and physical therapy.

18 Oct 2013

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company's U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB).

18 Oct 2013

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, will present data from the G-202 Phase I clinical trial at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA on Monday, October 21st.

18 Oct 2013

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.

18 Oct 2013

Use of effective, risky drug therapies by Medicare patients varies across US

A new report from the Dartmouth Atlas Project shows that the use of both effective and risky drug therapies by Medicare patients varies widely across U.S. regions, offering further evidence that location is a key determinant in the quality and cost of the medical care that patients receive.

18 Oct 2013

Atorvastatin drug plus zoledronic acid may help treat toxoplasmosis

Researchers at the University of Georgia have discovered that a combination of two commonly prescribed drugs used to treat high cholesterol and osteoporosis may serve as the foundation of a new treatment for toxoplasmosis, a parasitic infection caused by the protozoan Toxoplasma gondii. They published their findings recently in PLOS Pathogens.

18 Oct 2013

Therapy News and Research

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

New prognostic tool forecasts survival of patients with advanced prostate cancer

Valley Presbyterian Hospital doc awarded 2013 Achievement Award in Diabetic Limb Salvage

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

CBT more effective in reducing symptoms of health anxiety

Recombinant hormone could REPLACE calcium supplements

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Genalyte receives NCI grant to develop biomarker panel to profile TAA autoantibodies

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Vertebral augmentation for spinal fractures improves patient survival, reduces overall costs

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Use of effective, risky drug therapies by Medicare patients varies across US

Atorvastatin drug plus zoledronic acid may help treat toxoplasmosis

Inducing asthma control key to long-term outcomes

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News